Ad
related to: essential thrombocythemia treatment guidelines- About Chronic ITP
Learn More About What It Is
& How It Is Treated.
- Join For Exclusive Tips
Sign Up For Our Community Tips
Delivered To Your Doorstep & Inbox
- Connect With Coordinators
Click To Download Our Forms
Or Get Assistance.
- View Prescribing Info
Click To Find Full Prescribing
Info For This Medication.
- About Chronic ITP
Search results
Results from the WOW.Com Content Network
Essential thrombocythemia is sometimes described as a slowly progressive disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic events. [15] However, well-documented medical regimens can reduce and control the number of platelets, which reduces the risk of these thrombotic or hemorrhagic events.
Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. [2]
However, in essential thrombocythemia where platelet counts are over 750x10 9 /L or 1,000x10 9 /L, especially if there are other risk factors for thrombosis, treatment may be needed. Selective use of aspirin at low doses is thought to be protective.
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
It is indicated for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis [post-polycythemia vera and post-essential thrombocythemia], in adults with anemia. [31] [32]
Hydroxycarbamide, also known as hydroxyurea, is an antimetabolite medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. [4] [5] In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. [4] It is taken by mouth. [4]
Similarly, myeloproliferative disorders, in which the bone marrow produces too many blood cells, predispose to thrombosis, particularly in polycythemia vera (excess red blood cells) and essential thrombocytosis (excess platelets). Again, these conditions usually warrant specific treatment when identified. [21]
Chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, acute myeloid leukemia, allergic reactions or chronic inflammation related to infections, inflammatory bowel disease, and autoimmune disease. Diagnostic method: Complete blood count and blood smear.
Ad
related to: essential thrombocythemia treatment guidelines